Search In this Thesis
   Search In this Thesis  
العنوان
The Efficacy of Using chromium Salts
in Reducing Hirsutism Scoring & BMI
in Polycystic Ovary Syndrome Patients
A Randomized Controlled Trial/
المؤلف
Eid,Heba Mohammed Salah
هيئة الاعداد
باحث / هبة حمةد صالح عيد ابراهيم
مشرف / ديها حييي مهصور
مشرف / مروة صابرسيد
تاريخ النشر
2022
عدد الصفحات
179.p:
اللغة
الإنجليزية
الدرجة
ماجستير
التخصص
أمراض النساء والتوليد
تاريخ الإجازة
1/1/2022
مكان الإجازة
جامعة عين شمس - كلية التمريض - Obstetrics & Gynecology
الفهرس
Only 14 pages are availabe for public view

from 179

from 179

Abstract

lycystic ovary syndrome (PCOS) is one of the most
frequent endocrinopathies in women in reproductive age
and in adolescence. The causes of PCOS are still being studied;
there is an ongoing search for the genes responsible for the
manifestations of the disease, and the clinical image is
extraordinarily heterogeneous. There are gynecological and
metabolic symptoms; all of them influence patient’s
psychological condition and self-esteem (Kurek, 2017).
In the etiopathogenesis of PCOS, the role of insulin
resistance is emphasized as minimizing insulin resistance can
play a significant role in controlling PCOS which was an
indication for the attempts at using chromium III salts (Cr) in
augmenting pharmacotherapy applied in patients (Moghetti,
2016).
Chromium (III) is the synthetic salt form of Cr chloride
which is the naturally occurring trivalent variety of chromium
found in common food as broccoli, mushrooms and green
beans. Picolinic acid may serve to improve chromium
absorption (Yin and Phung, 2015).
This study was designed to assess the effect of chromium
salts in decreasing hirsutism scoring & Body Mass Index in
polycystic ovary syndrome patients. This prospective
randomized controlled clinical trial was conducted in Ain
P
Summary 
105
Shams University Maternity Hospital on polycystic ovary
syndrome patients attending gynecology or infertility outpatient
clinics started from November 2020 to May 2021. It included
60 women (aged between 18-40 years) diagnosed as PCOS
according to Rotterdam criteria with hyperandrogenism divided
into 2 groups, group S (30 patients) receiving chromium
(chromium picolinate, Mepaco) orally in a dose of
200microgram /day for 4 months’ duration, while group C (30
patients) received placebo (in the form of c retard capsules)
with both groups received metformin with dose of 500mg oral
tablets after main meal.
In the current study we found that there were no
significant differences between the two groups as regard age
and marital status as P-value was 0.925, 0.284 respectively,
there was insignificant difference between the two groups as
regard duration of infertility, acne, acanthosis and average no.
of cycles per year (p-value 0.915, 1.000, 1.000, 0.926
respectively).
There were no significant differences between study
groups as regard weight, BMI and hirsutism scoring at the start
of the study as P-value 0.580, 0.648, 0.159 respectively.